NO20080893L - A CA6 antigen-specific, cytotoxic conjugate and methods for using the same - Google Patents

A CA6 antigen-specific, cytotoxic conjugate and methods for using the same

Info

Publication number
NO20080893L
NO20080893L NO20080893A NO20080893A NO20080893L NO 20080893 L NO20080893 L NO 20080893L NO 20080893 A NO20080893 A NO 20080893A NO 20080893 A NO20080893 A NO 20080893A NO 20080893 L NO20080893 L NO 20080893L
Authority
NO
Norway
Prior art keywords
antigen
methods
specific
same
cytotoxic conjugate
Prior art date
Application number
NO20080893A
Other languages
Norwegian (no)
Inventor
Daniel J Tavares
Gillian Payne
Philip Chun
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of NO20080893L publication Critical patent/NO20080893L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20080893A 2005-08-22 2008-02-20 A CA6 antigen-specific, cytotoxic conjugate and methods for using the same NO20080893L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/030115 WO2007024222A1 (en) 2005-08-22 2005-08-22 A ca6 antigen-specific cytotoxic conjugate and methods of using the same

Publications (1)

Publication Number Publication Date
NO20080893L true NO20080893L (en) 2008-05-22

Family

ID=37771883

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080893A NO20080893L (en) 2005-08-22 2008-02-20 A CA6 antigen-specific, cytotoxic conjugate and methods for using the same

Country Status (13)

Country Link
EP (1) EP1917034A4 (en)
JP (1) JP2009504193A (en)
CN (1) CN101242855A (en)
AU (1) AU2005335743A1 (en)
BR (1) BRPI0520509A2 (en)
CA (1) CA2615761A1 (en)
EA (1) EA020130B9 (en)
EC (1) ECSP088241A (en)
HK (1) HK1211965A1 (en)
IL (2) IL189628A0 (en)
MX (1) MX2008002607A (en)
NO (1) NO20080893L (en)
WO (1) WO2007024222A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
SI2953977T1 (en) * 2013-02-05 2018-02-28 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
US9989524B2 (en) 2013-02-05 2018-06-05 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
WO2014124026A1 (en) * 2013-02-05 2014-08-14 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
JP2016515093A (en) * 2013-02-05 2016-05-26 サノフイ Immunoimaging agents for use with antibody-drug conjugate therapy
KR20160035600A (en) * 2013-08-02 2016-03-31 사노피 Use of anti-muc1 maytansinoid immunoconjugate antibody for the treatment of solid tumors
JP2017526682A (en) 2014-09-02 2017-09-14 イミュノジェン， インコーポレイテッド Method for formulating antibody drug conjugate composition
EP3189057A1 (en) 2014-09-03 2017-07-12 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
CR20170111A (en) 2014-09-03 2017-05-23 Immunogen Inc CYTOTOXIC BENZODIAZEPIN DERIVATIVES
EP4335851A3 (en) 2015-11-25 2024-06-05 ImmunoGen, Inc. Pharmaceutical formulations and methods of use thereof
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
RU2765098C2 (en) 2017-02-28 2022-01-25 Иммуноджен, Инк. Maitanzinoid derivatives with self-splitting peptide linkers and their conjugates
US20180346488A1 (en) 2017-04-20 2018-12-06 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
JP2021508714A (en) 2017-12-28 2021-03-11 イミュノジェン・インコーポレーテッド Benzodiazepine derivative
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596503B1 (en) * 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
BRPI0410260A (en) * 2003-05-14 2006-05-16 Immunogen Inc drug conjugate composition
CN103145844B (en) * 2003-07-21 2016-08-03 伊缪诺金公司 CA6 antigen-specific cytotoxic conjugate and application process thereof

Also Published As

Publication number Publication date
IL189628A0 (en) 2008-06-05
AU2005335743A1 (en) 2007-03-01
HK1211965A1 (en) 2016-06-03
JP2009504193A (en) 2009-02-05
ECSP088241A (en) 2008-04-28
MX2008002607A (en) 2008-03-19
EA200800642A1 (en) 2008-08-29
EA020130B1 (en) 2014-08-29
CA2615761A1 (en) 2007-03-01
BRPI0520509A2 (en) 2009-05-12
EP1917034A1 (en) 2008-05-07
IL238798A0 (en) 2015-06-30
WO2007024222A1 (en) 2007-03-01
EP1917034A4 (en) 2009-04-29
EA020130B9 (en) 2014-10-30
CN101242855A (en) 2008-08-13

Similar Documents

Publication Publication Date Title
NO20080893L (en) A CA6 antigen-specific, cytotoxic conjugate and methods for using the same
HK1246200A1 (en) Beta-glucuronide drug linker conjugates
DK3276349T3 (en) HAPTENES, HAPTEN CONJUGATES, COMPOSITIONS THEREOF, AND METHODS FOR PRODUCING AND USING THEREOF
IL186521A0 (en) Nanoparticle-active ingredient conjugates
HK1198485A1 (en) Molecular conjugate
EP1816192A4 (en) LINKER FOR CONSTRUCTING mRNA-PUROMYCIN-PROTEIN CONJUGATE
IL191941A0 (en) Conjugate vaccines
FR2889449B1 (en) IMPLANTABLE PREPARATIONS
PL2298766T3 (en) Pharmaceutical formulations comrpising a substituted pyridine derivative
EP1938760A4 (en) Suturing device
IL222915A0 (en) Improved tuberculosis vaccines
DK1937332T3 (en) Infusion apparatus and actuator thereto
DK2121713T3 (en) Oligosaccharides, comprising an amino group and conjugates thereof
EP1718335A4 (en) Drug conjugates
GB0501690D0 (en) Articulating device
EP2025667A4 (en) 9,10-secopregnane derivative and pharmaceutical
PL1736119T3 (en) Voice prosthesis device
PL1733703T3 (en) Voice prosthesis device
EP1904064A4 (en) Omeprazole form b
TWI372053B (en) Combination drug
ZA200805298B (en) Conjugate vaccines
DE602004012275D1 (en) for the production thereof and vaccine derivatives thereof
HK1073580A1 (en) Upright positioning device.
SI2298766T1 (en) Pharmaceutical formulations comrpising a substituted pyridine derivative
FIU20040069U0 (en) The linker

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: IMMUNOGEN, US

FC2A Withdrawal, rejection or dismissal of laid open patent application